| Literature DB >> 28450705 |
Gina M Sizemore1,2, Jason R Pitarresi1,2, Subhasree Balakrishnan1,2, Michael C Ostrowski1,2.
Abstract
Findings over the past decade have identified aberrant activation of the ETS transcription factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene rearrangement and amplification, feed-forward growth factor signalling loops, formation of gain-of-function co-regulatory complexes and novel cis-acting mutations in ETS target gene promoters can result in increased ETS activity. In turn, pro-oncogenic ETS signalling enhances tumorigenesis through a broad mechanistic toolbox that includes lineage specification and self-renewal, DNA damage and genome instability, epigenetics and metabolism. This Review discusses these different mechanisms of ETS activation and subsequent oncogenic implications, as well as the clinical utility of ETS factors.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28450705 DOI: 10.1038/nrc.2017.20
Source DB: PubMed Journal: Nat Rev Cancer ISSN: 1474-175X Impact factor: 60.716